ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0857

Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory

Michelle Petri1, Jessica Li2, Kelley Brady3, John Conklin4, Tyler O'Malley5 and Thierry Dervieux6, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD, 3Exagen Diagnostics, San Diego, CA, 4Exagen Inc., Vista, CA, 5Exagen, Inc, San Diego, CA, 6Prometheus Biosciences, Inc. (former employee of Exagen Diagnostics), Irvine, CA

Meeting: ACR Convergence 2020

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Session Title: SLE – Treatment Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Therapeutic blood monitoring is not yet an accepted practice in rheumatology. Although hydroxychloroquine (HCQ) blood level monitoring has been utilized in limited pharmacokinetic studies for some time, evidence for the utility of HCQ therapeutic blood monitoring in clinical practice has accumulated in recent years. Blood levels, rather than plasma levels, accurately reflect exposure and measure adherence over the last month.  HCQ blood levels predict retinopathy (Arthritis Rheumatol 2020;72:448–53) but also predict benefit, such as prevention of thrombosis (Abstract OP0160, European e-Congress of Rheumatology 2020, June 3-7).  We compared HCQ blood levels from the same visit done at two laboratories to ascertain agreement.

Methods: All patients met revised ACR or SLICC classification criteria for SLE.  Of the 114 patients included, 15 patients had 1 visit, 27 2 visits, 71 3 visits, and 1 patient 4 visits for a total of 286 visits. Patients were 85% female, 37% African American, and 51% Caucasian. HCQ blood levels were measured using the method of Füzéry et al. (Clin Chim Acta 2013;421:79–84) with a coefficient of variation < 3%, and at Exagen Diagnostics using liquid chromatography coupled to mass spectrometry (AVISE® HCQ).  The Bland-Altman plot was generated using R package BlandAltmanLe.  Intra-class correlation coefficient (ICC) was calculated using irr package in R version 3.6.1. Deming regression was performed using mcr package in R. Confidence bounds (95%) were calculated with the bootstrap method.

Results: Figure 1 shows the comparison of the University HCQ blood levels to the commercial HCQ blood levels. The Bland Altman plot showed the difference between the two measures of HCQ blood level of each patient against the average of the two measures (Figure 2). The mean difference between the two methods was -13.9, 95% limits of agreement were (-529.3, 501.5), and 4.2% (n=12) data points fell outside of the confidence limits. Intra-class correlation coefficient was used to calculate an estimate of the overall agreement between the two measurements. The ICC was 0.923 (0.904, 0.938). Deming regression was used to look at systematic differences between the two HCQ blood level measurement methods (Figure 3).  The slope of best fit was 1.12 with 95% confidence limits of (0.99, 1.22).

Conclusion: There is excellent agreement between a university and commercial laboratory in measuring HCQ blood levels.  Clinicians can be confident in the reliability of the hydroxychloroquine blood level. This should increase acceptance and utilization.  Hydroxychloroquine blood levels have proven there is a “therapeutic window” to maintain benefit and still reduce risk of retinopathy.

Comparison of the University Hydroxychloroquine Blood Levels to the Exagen Hydroxychloroquine Blood Levels

Bland-Altman Plot Showing Differences Between the Two Measures of Hydroxychloroquine Blood Level

Deming Regression Plot Looking at Systematic Differences Between the Two Hydroxychloroquine Blood Level Measurement Methods


Disclosure: M. Petri, Astrazeneca, 2, 5, Exagen, 2, 5, GlaxoSmithKline (GSK), 2, 5, Eli Lilly and Company, 2, 5, AbbVie Inc., 5, Aleon Pharma International, Inc, 5, Amgen, 5, Annenberg Center for Health Sciences,, 5, Blackrock Pharma, 5, Bristol Myers Squibb, 5, Decision Resources, 5, Glenmark Pharmaceuticals, 5, INOVA, 5, IQVIA, 5, Janssen Pharmaceutical, 5, Merck EMD Serono, 5, Novartis, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5; J. Li, None; K. Brady, Exagen Inc., 1, 3; J. Conklin, Exagen, 1, 2; T. O'Malley, Exagen, 1, 2; T. Dervieux, Exagen, 1.

To cite this abstract in AMA style:

Petri M, Li J, Brady K, Conklin J, O'Malley T, Dervieux T. Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/agreement-of-hydroxychloroquine-blood-levels-between-a-university-and-commercial-laboratory/. Accessed March 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/agreement-of-hydroxychloroquine-blood-levels-between-a-university-and-commercial-laboratory/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences